Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AIM

AIM ImmunoTech Inc

Mar 13 • 12:48PM ET

0.1230

Dollar change -0.0004
Percentage change -0.32	%

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ LLY PFE AZN MRNA BMY GILD AMGN REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	11.81%	Shs Outstand	68.75M	Perf Week	-8.41%
Market Cap	8.45M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	6.27%	Shs Float	60.63M	Perf Month	-18.22%
Income	-23.93M	PEG	-	EPS next Q	-0.09	Inst Own	6.76%	Short Float	5.42%	Perf Quarter	-43.94%
Sales	0.19M	P/S	44.49	EPS this Y	50.00%	Inst Trans	-17.90%	Short Ratio	3.01	Perf Half Y	-62.14%
Book/sh	0.05	P/B	2.48	EPS next Y	-16.67%	ROA	-115.46%	Short Interest	3.29M	Perf Year	-65.83%
Cash/sh	0.10	P/C	1.17	EPS next 5Y	-	ROE	-187.58%	52W Range	0.11 - 0.62	Perf YTD	-37.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.86%	ROI	-686.04%	52W High	-80.16%	Beta	0.76
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	11.74%	Gross Margin	-45.26%	52W Low	11.31%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.75	EPS Y/Y TTM	-10.16%	Oper. Margin	-14687.89%	RSI (14)	38.01	Volatility	11.86% 14.32%
Employees	26	Debt/Eq	1.17	Sales Y/Y TTM	-1.55%	Profit Margin	-12594.21%	Recom	1.00	Target Price	4.50
Option/Short	No / No	LT Debt/Eq	0.20	EPS Q/Q	60.05%	Payout	-	Rel Volume	0.59	Prev Close	0.12
Sales Surprise	-100.00%	EPS Surprise	0.00%	Sales Q/Q	-23.91%	Earnings	Nov 19 BMO	Avg Volume	1.09M	Price	0.12
SMA20	-5.96%	SMA50	-27.93%	SMA200	-54.23%	Trades		Volume	343,770	Change	-0.32%

Mar-11-25 08:45AM	AIM ImmunoTech Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-28-25 08:45AM	AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza (GlobeNewswire) +5.55%
Feb-26-25 01:20PM	AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) +9.60%
08:30AM	AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director (GlobeNewswire)
Feb-25-25 08:30AM	AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire) -7.47%
08:45AM	Loading…
Feb-11-25 08:45AM	AIM ImmunoTech Releases Virtual Investor What This Means Segment (GlobeNewswire) +5.84%
08:30AM	AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (GlobeNewswire)
Feb-07-25 08:50AM	AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenza outbreaks (GlobeNewswire)
Feb-05-25 08:00AM	Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire) -20.88%
Jan-23-25 08:50AM	AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions (GlobeNewswire)
Jan-22-25 08:30AM	AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS (GlobeNewswire)
Jan-17-25 12:00PM	AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +8.42%
Jan-15-25 09:05AM	AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones (GlobeNewswire)
Dec-17-24 04:45PM	AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards (GlobeNewswire) -6.89%
03:10PM	AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting (Business Wire)
08:00AM	Loading…
Dec-16-24 08:00AM	AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card (Business Wire)
Dec-14-24 04:54PM	Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board (GlobeNewswire)
Dec-13-24 03:48PM	UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card (GlobeNewswire)
Dec-12-24 03:00PM	AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members (Business Wire)
09:00AM	AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue (GlobeNewswire)
08:16AM	Kellner Group Announces Support from Another Former AIM Senior Executive (GlobeNewswire)
Dec-11-24 07:30AM	AIMs Clinical Strategy Under Incumbent Board Has Totally Failed (GlobeNewswire)
Dec-10-24 10:20AM	Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell (Business Wire)
07:30AM	Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected (GlobeNewswire)
Dec-06-24 09:15AM	AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment (GlobeNewswire)
08:34AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card (GlobeNewswire)
Dec-05-24 09:00AM	ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell (Business Wire)
Dec-02-24 08:00AM	AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Groups Nominees to the Board (Business Wire) -5.69%
07:30AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card (GlobeNewswire)
Nov-28-24 08:10AM	AIM ImmunoTech announces cash conservation plan, committment to Ampligen (TipRanks)
03:30PM	Loading…
Nov-27-24 03:30PM	AIM ImmunoTech Refutes Activist Groups False and Misleading Claims (Business Wire)
08:00AM	AIM ImmunoTech Announces Cash Conservation Plan (Business Wire)
Nov-26-24 07:00AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Enclosed Gold Card (GlobeNewswire) +5.63%
Nov-25-24 08:00AM	AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders (Business Wire)
Nov-20-24 11:50AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board (PR Newswire) +9.29%
Nov-19-24 08:00AM	AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer (GlobeNewswire) -20.57%
07:00AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board (GlobeNewswire)
Nov-16-24 02:01AM	AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Nov-15-24 07:29AM	AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -11.75%
Nov-06-24 09:00AM	AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast (GlobeNewswire)
Nov-04-24 08:00AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire)
Oct-09-24 09:00AM	AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire)
Oct-03-24 08:45AM	AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis (GlobeNewswire)
Sep-30-24 09:00AM	AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering (GlobeNewswire)
Sep-27-24 08:00AM	AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-19-24 08:00AM	AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
Sep-11-24 09:00AM	AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue (GlobeNewswire)
Aug-20-24 08:30AM	AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire) +15.32%
Aug-16-24 07:00AM	AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-24 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Jul-29-24 09:15AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Jul-24-24 08:50AM	AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy (GlobeNewswire) -7.22%
Jul-03-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +6.49%
Jun-10-24 08:55AM	AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference (GlobeNewswire) -6.35%
Jun-03-24 09:15AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-31-24 08:30AM	AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire)
May-20-24 09:15AM	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-16-24 07:30AM	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 08:50AM	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast (GlobeNewswire)
May-06-24 08:30AM	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen (GlobeNewswire)
Apr-29-24 08:55AM	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer (GlobeNewswire)
Apr-25-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) -5.47%
Apr-18-24 08:45AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Apr-15-24 08:55AM	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs (GlobeNewswire) -13.74%
Apr-11-24 11:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +10.05%
Apr-10-24 08:21AM	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer (GlobeNewswire) +12.96%
Apr-02-24 07:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.18%
Mar-28-24 08:05AM	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire) +6.32%
Mar-26-24 09:05AM	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Mar-25-24 09:05AM	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire)
Mar-22-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +16.46%
Mar-20-24 09:25AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Mar-15-24 08:45AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity (GlobeNewswire)
Mar-07-24 08:45AM	AIM ImmunoTech Announces Launch of CEO Corner Platform (GlobeNewswire)
Feb-29-24 08:45AM	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update (GlobeNewswire)
Feb-14-24 08:55AM	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Feb-08-24 08:50AM	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) -12.64%
Jan-24-24 09:10AM	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire) -6.88%
Jan-22-24 08:55AM	AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZenecas Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire)
Jan-10-24 08:45AM	AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jan-05-24 01:32PM	AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting (Business Wire) -8.14%
Jan-03-24 04:05PM	Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied (PR Newswire)
Dec-29-23 08:00AM	Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Boards Determination that Activist Groups Nominations Are Invalid (Business Wire) -8.73%
Nov-28-23 04:30PM	AIM ImmunoTech Provides Update Regarding Annual Meeting (Business Wire) +7.27%
Nov-27-23 09:00PM	AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents (GlobeNewswire)
Nov-21-23 12:00PM	AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Nov-16-23 08:45AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change (PR Newswire)
Nov-15-23 07:30AM	AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
Nov-14-23 10:00AM	AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer (GlobeNewswire)
Nov-09-23 08:05AM	AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast (GlobeNewswire) -8.12%
Nov-08-23 08:45AM	AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Nov-06-23 09:25AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire) -8.99%
Oct-30-23 08:55AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) +6.98%
Oct-17-23 08:45AM	AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs (GlobeNewswire) +10.43%
Sep-22-23 09:05AM	AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (GlobeNewswire)
Sep-11-23 01:00PM	AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) +7.97%
Sep-05-23 09:05AM	AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 08:00AM	AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements (Business Wire)
Aug-15-23 06:45AM	AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update (GlobeNewswire) -6.34%
Aug-09-23 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Mar 05 '25	Buy	0.13	50,000	6,730	1,858,029	Mar 06 09:36 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	44,000	5,060	1,808,029	Mar 05 10:00 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	83,334	10,000	1,764,029	Mar 04 01:14 PM
Equels Thomas K	CEO & President	Nov 21 '24	Buy	0.21	20,000	4,240	1,657,968	Jan 21 04:32 PM
MITCHELL WILLIAM M	Director	Dec 19 '24	Sale	0.19	4,580	884	118,549	Dec 20 04:30 PM
Equels Thomas K	CEO & President	Dec 18 '24	Buy	0.21	22,727	4,682	1,680,695	Dec 19 01:38 PM
APPELROUTH STEWART	Director	Dec 02 '24	Buy	0.21	11,112	2,356	355,509	Dec 04 04:05 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.20	85,000	16,915	1,637,968	Nov 21 12:04 PM
APPELROUTH STEWART	Director	Nov 20 '24	Buy	0.19	81,953	15,817	321,752	Nov 21 12:02 PM
Equels Thomas K	CEO & President	Nov 20 '24	Buy	0.18	60,110	11,000	1,552,968	Nov 20 12:46 PM
Equels Thomas K	CEO & President	Sep 16 '24	Buy	0.30	5,000	1,515	1,493,042	Sep 17 12:05 PM
Equels Thomas K	CEO & President	Sep 13 '24	Buy	0.31	20,000	6,160	1,488,042	Sep 16 03:45 PM
Equels Thomas K	CEO & President	May 06 '24	Buy	0.41	61,729	25,000	778,184	May 07 08:30 AM
Rodino Peter W III	COO, Secretary, Gen. Counsel	May 06 '24	Buy	0.41	30,865	12,500	212,583	May 07 08:30 AM
BRYAN NANCY	Director	Mar 21 '24	Buy	0.39	38,462	15,000	38,462	Mar 22 01:30 PM
APPELROUTH STEWART	Director	Mar 15 '24	Buy	0.33	90,910	30,000	239,765	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Mar 15 '24	Buy	0.33	75,758	25,000	716,455	Mar 18 03:01 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Mar 15 '24	Buy	0.33	37,879	12,500	181,718	Mar 18 03:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience